Recombinant Meyerozyma guilliermondii NADH-cytochrome b5 reductase 1 (CBR1)

Basic Research Questions

• How is Meyerozyma guilliermondii taxonomically classified and what methods are used for identification?

  Meyerozyma guilliermondii is a yeast species previously known as Candida guilliermondii in its anamorphic (asexual) state . It belongs to the taxonomic hierarchy:

  • Domain: Eukarya

  • Kingdom: Fungi

  • Phylum: Ascomycota

  • Class: Saccharomycetes

  • Order: Saccharomycetales

  • Family: Debaryomycetaceae

  • Genus: Meyerozyma

  • Species: M. guilliermondii

  For accurate identification, molecular methods are recommended over phenotypic methods, which frequently misidentify species within the M. guilliermondii complex . The following identification methods are commonly used:

  1. ITS Sequencing: The internal transcribed spacer (ITS1-5.8S-ITS2) region sequencing is the gold standard .

  2. ITS-RFLP Analysis: Restriction fragment length polymorphism of the ITS region using TaqI enzyme can distinctly differentiate M. guilliermondii from closely related species like M. caribbica .

  3. MALDI-TOF MS: Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry is capable of accurately identifying this species .

  4. Microscopy: Spherical to subspherical budding yeast-like cells or blastoconidia, 2.0-4.0 x 3.0-6.5 µm. Branched pseudohyphae with dense verticils of blastoconidia can be observed in Dalmau plate culture .

• What are the regulatory considerations for working with recombinant M. guilliermondii proteins in academic research settings?

  Research involving recombinant proteins from M. guilliermondii falls under the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules . Key regulatory considerations include:

  1. Biosafety Level: M. guilliermondii is classified as a Risk Group 1 (RG-1) organism , requiring Biosafety Level 1 (BSL-1) containment for most research applications.

  2. IBC Approval Requirements: Experiments involving the creation of recombinant proteins require Institutional Biosafety Committee (IBC) review and approval before initiation .

  3. NIH Guidelines Sections: Research with recombinant M. guilliermondii proteins typically falls under:

     • Section III-E-3 for experiments involving rodents at BL1 containment

     • Section III-D-4 for experiments requiring higher containment levels

  4. Documentation Requirements: Permanent records must be maintained for experimental use and disposal of recombinant materials .

  5. Recent Updates: Researchers should note that NIH Guidelines have been updated with new requirements effective September 30, 2024, particularly regarding gene drive modified organisms (GDMOs) .

• What expression systems are typically used for producing recombinant M. guilliermondii CBR1?

  Several expression systems can be used to produce recombinant M. guilliermondii CBR1, each with specific advantages:

  1. E. coli Expression System: Most commonly used due to rapid growth, high protein yields, and well-established protocols.

  2. Yeast Expression Systems: Saccharomyces cerevisiae or Pichia pastoris are effective for expressing eukaryotic proteins with proper folding and post-translational modifications.

  3. Insect Cell/Baculovirus System: Provides eukaryotic processing capabilities and is useful for complex proteins.

  4. Mammalian Cell Expression: HEK293 cells can be used when mammalian post-translational modifications are critical.

  Recombinant CBR1 is typically tagged during production to facilitate purification, with common tag options including His, GST, DDK, Myc, Flag, Avi, and Fc tags . The final product is typically stored in Tris-based buffer with 50% glycerol at -20°C or -80°C for extended storage .